Beneficial effects of probiotic combination with omega-3 fatty acids in NAFLD: a randomized clinical study
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The manipulation of gut microbiota via administration of probiotics has been proposed as a potential strategy for the treatment of non-alcoholic fatty liver disease (NAFLD). Hence, we performed a double-blind single center randomized placebo-controlled trial (RCT) to evaluate the efficacy of coadministration of probiotics with omega-3 vs. placebo in type-2 diabetic patients with NAFLD. METHODS: A total of 48 patients met the criteria for inclusion. They were randomly assigned to receive "Symbiter Omega" combination of probiotic biomass supplemented with flax and wheat germ oil (250 mg of each, concentration of omega-3 fatty acids 1-5%) or placebo for 8-weeks. The primary main outcomes were the change in fatty liver index (FLI) and liver stiffness (LS) measured by Shear Wave Elastography (SWE). Secondary outcomes were the changes in transaminases level, serum lipids and cytokines levels. RESULTS: In probiotic-omega group, FLI significantly decreased from 83.53±2.60 to 76.26±2.96 (P<0.001) while no significant changes were observed in the placebo group (82.86±2.45 to 81.09±2.84; P=0.156). Changes of LS in both groups were insignificant. Analysis of secondary outcomes showed that the coadministration of probiotics with omega-3 lead to significant reduction of serum gamma-glutamyl transpeptidase, triglycerides, and total cholesterol. Chronic systemic inflammatory markers after intervention decrease significantly only in Symbiter Omega group: IL-1β (P=0.029), TNF-α (P<0.001), IL-8 (P=0.029), IL-6 (P=0.003), and INF-γ (P=0.016). CONCLUSIONS: Coadministration of a live multi-strain probiotic mixture with omega-3 fatty acids once daily for 8 weeks to patients with NAFLD can reduce liver fat, improve serum lipids, metabolic profile, and reduce chronic systemic inflammatory state.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327
Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis
Rolo, A. P., Teodoro, J. S., & Palmeira, C. M. (2012) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2011.10.003 · Cited by 955
A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis
Promrat, K., Lutchman, G., Uwaifo, G. I., Freedman, R. J., Soza, A., Heller, T., Doo, E., Ghany, M., Premkumar, A., Park, Y., et al. (2004) · Hepatology · doi:10.1002/hep.20012 · Cited by 726
Metformin in non-alcoholic steatohepatitis.
Marchesini, G., Bianchi, G., Tomassetti, S., Zoli, M., & Melchionda, N. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06042-1 · Cited by 682
Omega-3 supplementation and non-alcoholic fatty liver disease: A systematic review and meta-analysis
Parker, H. M., Johnson, N. A., Burdon, C. A., Cohn, J. S., O’Connor, H. T., & George, J. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.08.018 · Cited by 569
Effects of probiotics on nonalcoholic fatty liver disease: A meta-analysis
Ma, Y.-Y. (2013) · World Journal of Gastroenterology · doi:10.3748/wjg.v19.i40.6911 · Cited by 352
Rajkumar, H., Mahmood, N., Kumar, M., Varikuti, S. R., Challa, H. R., & Myakala, S. P. (2014) · Mediators of Inflammation · doi:10.1155/2014/348959 · Cited by 301
Omega-3 polyunsaturated fatty acids as a treatment strategy for nonalcoholic fatty liver disease
Jump, D. B., Lytle, K. A., Depner, C. M., & Tripathy, S. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.07.007 · Cited by 142
Reversal of high-fat diet-induced hepatic steatosis by n-3 LCPUFA: Role of PPAR-α and SREBP-1c
Dossi, C. G., Tapia, G. S., Espinosa, A., Videla, L. A., & D'Espessailles, A. (2014) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2014.04.011 · Cited by 51
Cited by
High fat diet-triggered non-alcoholic fatty liver disease: A review of proposed mechanisms
Lian, C.-Y., Zhai, Z.-Z., Li, Z.-F., & Wang, L. (2020) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2020.109199 · Cited by 302
Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD)
Rong, L., Zou, J., Ran, W., Qi, X., Chen, Y., Cui, H., & Guo, J. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1087260 · Cited by 301
Effects of probiotics on nonalcoholic fatty liver disease: a systematic review and meta-analysis
Tang, Y., Huang, J., Zhang, W. Y., Qin, S., Yang, Y. X., Ren, H., Yang, Q.-B., & Hu, H. (2019) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756284819878046 · Cited by 85
“25 40 (38) 39 (39) DFI, TC, HDL-C, LDL-C, TG”
Buchynskyi, M., Kamyshna, I., Halabitska, I., Petakh, P., Kunduzova, O., Oksenych, V., & Kamyshnyi, O. (2025) · Frontiers in Microbiology · doi:10.3389/fmicb.2025.1577724 · Cited by 30
Nutritional supplementation for nonalcohol-related fatty liver disease: a network meta-analysis
Komolafe, O., Buzzetti, E., Linden, A., Best, L. M., Madden, A. M., Roberts, D., Chase, T. J., Fritche, D., Freeman, S. C., Cooper, N. J., et al. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013157.pub2 · Cited by 21
Metadata
- Authors
- Kobyliak, N., Abenavoli, L., Falalyeyeva, T., Mykhalchyshyn, G., Boccuto, L., Kononenko, L., Kyriienko, D., Komisarenko, I., & Dynnyk, O.
- Venue
- Minerva Medica
- Publisher
- Edizioni Minerva Medica
- Published
- 2018-12
- Volume
- 109
- Issue
- 6
- Pages
- 418-428
- ISSN
- 0026-4806 (ISSN-L)
- 1827-1669
- OpenAlex
- W2904601309
- Cited by
- 108
- References
- 9
- FWCI
- 9.89
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Beneficial effects of probiotic combination with omega-3 fatty acids in NAFLD: a randomized clinical study. https://app.cochat.ai/papers/10.23736/s0026-4806.18.05845-7
- The paper
- Kobyliak, N., Abenavoli, L., Falalyeyeva, T., Mykhalchyshyn, G., Boccuto, L., Kononenko, L., Kyriienko, D., Komisarenko, I., & Dynnyk, O. (2018). Beneficial effects of probiotic combination with omega-3 fatty acids in NAFLD: a randomized clinical study. Minerva Medica. https://doi.org/10.23736/s0026-4806.18.05845-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.